Improving Prostate Cancer Patient Care in the Clinical Setting

Presented by Jessica Deinert, MSN, APRN, FNP-C, AOCNP®, and Leah K. Shaw, MSN, APRN, AGPCNP-BC

At JADPRO Live 2023 in Orlando, presenters provided an overview of best practices in the diagnosis, classification, and management of patients with localized and metastatic prostate cancer. They covered selecting appropriate therapies ba...

Management of Advanced Prostate Cancer With Relugolix: Illustrative Case Scenarios From an Advanced Practice Provider Perspective

Jared Thorley,(1) APRN, MSN, FNP, and Saneese Stephen,(2) MPAS, PA-C, MPA

Prostate cancer is the second most common cause of cancer-related mortality among men in the United States, with an estimated 34,700 deaths annually. Androgen deprivation therapy (ADT) is the cornerstone of advanced prostate cancer thera...

Prostate Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner

Morgane C. Diven, PharmD, BCOP

Morgane C. Diven, PharmD, BCOP, of Phoenix VA Health Care System, evaluates research on an investigational radiolabeled small molecule, combination therapy in the treatment of de novo metastatic prostate cancer, and a CYP17-lyase inhibit...

Advanced Prostate Cancer: Considerations for Advanced Practitioners

Presented by Brenda Martone, MSN, ANP-BC, AOCNP®

At JADPRO Live Virtual 2020, Brenda Martone, MSN, ANP-BC, AOCNP®, discussed treatment options available for advanced prostate cancer patients and the role of genetics and genomics in patients with advanced prostate cancer. 

Prostate Cancer: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner

Morgane C. Diven, PharmD, BCOP

Morgane C. Diven, PharmD, BCOP, of Phoenix VA Health Care System, breaks down abstract summaries published in The ASCO Post on a novel target, imaging agent, and androgen-deprivation therapy for prostate cancer, along with their implicat...

2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Prostate Cancer

Jennifer L. Glass, PA-C, MS

Following coverage by The ASCO Post, Jennifer L. Glass, PA-C, MS, of the Mayo Clinic dives into the major findings in prostate cancer from the 2019 ASCO Annual Meeting in Chicago and their implications for advanced practitioners.

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Urvi J. Patel, PharmD, MPH, and Sarah Caulfield, PharmD, BCOP

Abstract Prostate cancer is the fourth leading cause of cancer in the United States. Treatment of this oncologic disease involves a variety of different modalities including surgery, radiation, and systemic therapy. Systemic therapy is ...

Therapeutic Advances in Prostate Cancer

Presented by Robert Dreicer, MD, MS, MACP, FASCO, and Morgane C. Diven, PharmD, BCOP

Robert Dreicer, MD, MS, MACP, FASCO, and Morgane C. Diven, PharmD, BCOP, discussed the emerging data regarding the role of genomics in metastatic castration-sensitive and -resistant prostate cancer, as well as strategies to manage the to...

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen

Enzalutamide: A New Agent for the Prostate Cancer Treatment Armamentarium

The development of disease resistance to current drugs underlies the need for additional treatment options in metastatic prostate cancer. Learn the key facts about enzalutamide (Xtandi), recently approved for use in patients with castrat...

Screening for Prostate Cancer: The Debate Continues

Other than skin cancer, prostate cancer is the most frequently diagnosed cancer in men, and it is the second leading cause of cancer-related death for males in the United States. Screening for prostate cancer using prostate-specific anti...

Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer

Mr. R., a 70-year-old man, presented to the emergency department of our hospital with urinary retention and acute renal failure in April 2011. On presentation, his prostate-specific antigen (PSA) level was 2,628.2 ng/mL. He was examined ...

Can You Determine the Cause of This Patient’s Skin Changes?

Abiraterone Acetate in Castrate-Recurrent Prostate Cancer

Cabazitaxel

Radical Prostatectomy for the Treatment of Moderate to Severe Lower Urinary Tract Symptoms in Organ-Confined Prostate Cancer

A diagnosis of prostate cancer in men who have moderate to severe lower urinary tract symptoms (LUTS) frequently results in a recommendation to undergo radical prostatectomy. The rationale for this recommendation is that removal of the p...

Biomarkers in Prostate Cancer

Prostate cancer represents the most common noncutaneous cancer in men in the United States. Although PSA testing with or without digital exam has led to increased prostate cancer detection, it continues to lack specificity, which leads t...

Sipuleucel-T: A New Advance in the Treatment of Castrate-Resistant Prostate Cancer